Sulindac

Generic Name
Sulindac
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H17FO3S
CAS Number
38194-50-2
Unique Ingredient Identifier
184SNS8VUH
Background

Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.

Indication

For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis.

Associated Conditions
Ankylosing Spondylitis (AS), Colorectal Adenomas, Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Tendonitis exacerbated, Acute Subacromial bursitis, Acute supraspinatus tendinitis
Associated Therapies
-

A Randomized Study of Sulindac in Oral Premalignant Lesions

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2006-03-06
Last Posted Date
2020-11-19
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
63
Registration Number
NCT00299195
Locations
🇮🇳

Amrita Institute of Sciences (AIMS), Cochin, India

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇮🇳

Regional Cancer Center (RCC), Trivandrum, India

Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Phase 1
Completed
Conditions
First Posted Date
2005-10-27
Last Posted Date
2013-05-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00245024
Locations
🇺🇸

Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States

The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon

Not Applicable
Terminated
Conditions
First Posted Date
2005-09-15
Last Posted Date
2009-12-11
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
60
Registration Number
NCT00176618
Locations
🇺🇸

Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

First Posted Date
2005-07-11
Last Posted Date
2015-01-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
375
Registration Number
NCT00118365
Locations
🇺🇸

University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

Sulindac and Plant Compounds in Preventing Colon Cancer

Not Applicable
Terminated
Conditions
First Posted Date
2004-05-21
Last Posted Date
2011-01-27
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Registration Number
NCT00003365
Locations
🇺🇸

Rockefeller University Hospital, New York, New York, United States

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

First Posted Date
2003-09-11
Last Posted Date
2020-02-19
Lead Sponsor
Children's Oncology Group
Target Recruit Count
70
Registration Number
NCT00068419
Locations
🇺🇸

Children's Oncology Group, Monrovia, California, United States

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

First Posted Date
2003-06-06
Last Posted Date
2012-07-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
12
Registration Number
NCT00062023
Locations
🇺🇸

M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

Phase 2
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2014-05-06
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
10
Registration Number
NCT00039520
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath